Russia Guidance – BE [Regulatives / Guidelines]

posted by Dr_Dan  – Germany, 2013-09-03 16:40 (4677 d 17:52 ago) – Posting: # 11417
Views: 11,926

Dear Karthikeyan
If your product satisfies the criteria of having the same qualitative and quantitative composition in terms of active principles, of having the same pharmaceutical form and of being equivalent then the generic nature is given and it is evident that all data available for the original product also apply for the preparation of your application. The whole information on pharmaco-toxicological and clinical experience can be transferred from the originator product to the Test product. This is the basis for generic applications. Please be advised that information on toxicology refers to the drug entity itself and not to the formulation of a drug. There will be no gain in scientific knowledge if you repeat toxicological tests for your formulation. However, you need to provide evidence that no new toxicologic data are available since marketing authorisation for the reference product was granted.
I hope this helps.
Kind regards
Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
115 visitors (0 registered, 115 guests [including 19 identified bots]).
Forum time: 10:33 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5